Edwards Lifesciences Corp Stock Price, News & Analysis

Edwards Lifesciences (NYSE: EW) reported Q3 2024 financial results with total sales growth of 9% (10% constant currency) from continuing operations. TAVR sales reached $1.0 billion, growing 6%, while TMTT sales showed significant growth of 73%. The company reported Q3 EPS of $5.13 and adjusted EPS of $0.67. The quarter was marked by the completion of Critical Care divestiture and continued progress in PASCAL and EVOQUE commercial launches. Edwards maintained its full-year 2024 sales guidance ranges and expects Q4 sales between $1.33-$1.39 billion with EPS of $0.53-$0.57.

Edwards Lifesciences (NYSE: EW) has announced plans to release its Q3 2024 operating results on October 24, 2024, after market close. The company will host a conference call at 5:30 p.m. ET to discuss the results. Investors can participate by dialing (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the company's investor relations website.

Edwards Lifesciences is a global leader in patient-focused innovations for structural heart disease. The company is committed to improving lives through partnerships with clinicians and healthcare stakeholders worldwide.

Endotronix, an Edwards Lifesciences company (NYSE: EW), announced one-year clinical results from the PROACTIVE-HF trial for the Cordella Pulmonary Artery (PA) Sensor System at the Heart Failure Society of America Annual Scientific Meeting. The study of 456 patients showed a 49% lower rate of heart failure hospitalization and all-cause mortality compared to pre-specified expectations.

Secondary endpoints also demonstrated significant improvements:

• 10.5% in Kansas City Cardiomyopathy Questionnaire
• 13.3% in 6-minute walk test
• 36.2% in New York Heart Association classification
• 5.7% reduction in NT-proBNP levels

These results further validate the previously published 6-month data, supporting the efficacy of PA pressure-guided therapy in improving heart failure outcomes.

Edwards Lifesciences (NYSE: EW) has completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) for $4.2 billion in cash. The company plans to use the proceeds for strategic initiatives, including acquisitions and share repurchases. CEO Bernard Zovighian emphasized the company's sharpened focus on structural heart innovation, highlighting growth opportunities in TAVR, TMTT, and surgical leadership.

Edwards also announced an additional $1.5 billion authorization for share repurchase. The company has already initiated a $500 million Accelerated Share Repurchase agreement and previously repurchased $500 million of common stock. After this $1 billion share repurchase, Edwards will have $1.4 billion remaining for future repurchases.

Edwards Lifesciences (NYSE: EW) announced results from the RHEIA Trial, the first all-female study comparing transcatheter aortic valve implantation (TAVI) to surgical aortic valve replacement (SAVR). The trial, involving 440 women with an average age of 73, showed superior outcomes for TAVI using Edwards SAPIEN 3 Ultra or SAPIEN 3 Ultra RESILIA valves compared to SAVR.

Key findings at one-year follow-up:

• TAVI group: 8.9% experienced death, stroke, or rehospitalization
• SAVR group: 15.6% experienced death, stroke, or rehospitalization

The study, conducted across 48 sites in 12 European countries, aims to address the underrepresentation of women in aortic stenosis treatment research and provide insights into their specific treatment options.

Edwards Lifesciences (NYSE: EW) announced results from the RHEIA Trial, the first all-female study focused on transcatheter aortic valve implantation (TAVI) outcomes. The trial, presented at ESC Congress 2024, showed superior outcomes for women receiving Edwards SAPIEN 3 or SAPIEN 3 Ultra valves compared to surgical aortic valve replacement (SAVR).

Key findings include:

• TAVI was superior to SAVR in 1-year composite endpoints
• 8.9% of TAVI patients experienced death, stroke, or rehospitalization vs 15.6% in SAVR
• 443 female patients with an average age of 73 were included
• Study conducted across 48 sites in 12 European countries

The trial highlights the importance of valve selection for women, especially those with small annuli, to preserve options for future valve-in-valve procedures.

Edwards Lifesciences (NYSE: EW), a global leader in patient-focused innovations for structural heart disease and critical care monitoring, has announced its participation in the 2024 Wells Fargo Healthcare Conference. The event is scheduled for Thursday, September 5, 2024, with CEO Bernard Zovighian and CFO Scott Ullem set to present at 10:15 a.m. ET.

A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible later the same day. This presentation offers an opportunity for investors and stakeholders to gain insights into Edwards Lifesciences' strategies and market position in the healthcare industry.

Edwards Lifesciences (NYSE: EW) announced strategic investments aimed at expanding its structural heart portfolio through the acquisition of JenaValve Technology and Endotronix. The company aims to strengthen its leadership in heart innovation and address large unmet patient needs.

JenaValve Technology specializes in transcatheter treatments for aortic regurgitation (AR), a deadly and largely untreated condition. Edwards expects FDA approval for the JenaValve Trilogy Heart Valve System in late 2025.

Endotronix, a leader in heart failure (HF) management, recently received FDA approval for Cordella, an implantable pulmonary artery pressure sensor. A CMS national coverage determination is anticipated in early 2025.

The acquisitions, valued at approximately $1.2 billion, are expected to provide minimal revenue contribution in 2025 and are subject to antitrust and foreign investment approvals.

Edwards Lifesciences (NYSE: EW) reported Q2 2024 financial results. Total sales grew 7%, with TAVR sales up 5%, and TMTT sales jumping 75%. Adjusted EPS was $0.70. The company expects full-year sales growth of 8-10%, but lowered TAVR guidance to 5-7%. TMTT guidance increased to the higher end of $320-$340 million. The sale of Critical Care for $4.2 billion is expected to close by late Q3 2024. Surgical Structural Heart sales rose 3%, led by INSPIRIS, MITRIS, and KONECT technologies. The adjusted gross profit margin was 77.1%, and the company ended the quarter with $2.0 billion in cash and $600 million in debt. Q3 sales are forecasted at $1.56-$1.64 billion with EPS of $0.67-$0.71.